Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, Tang M, Sun H, Elamin Y, Lacerda LC, Lewis J, Roth JA, Swisher SG , Lee JJ, William WN Jr, Glisson BS, Zhang J, Papadimitrakopoulou VA, Gray JE, Heymach JV
(37552484) [3] Sustained-release formulations: Guidelines state that charcoal may be useful even after 4 hours if evidence of ongoing absorption is present, e.g., an increasing acetaminophen concentration. (37552484) For an ingestion that was slightly beyond four hours ago, it might be reasonable to empirically give activated charcoal (especially if there is a delayed turnaround time on serial acetaminophen levels)
Methods: We performed a systematic literature search in clinicaltrials.gov and PubMed for all NAFLD therapeutic trials in the U.S
Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, MD, Garcia-Manero G, Borthakur GM, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Benton CB, Kadia TM, Takahashi K, Yilmaz ME, Jain N, Kornblau, SM, Montalban Bravo G, Sasaki K, Andreeff M , Bose P, Ferrajoli A, MD, Issa GC, Jabbour E, Masarova L, Rytting ME, Thompson P, Wang SA, Konoplev S, Chen Z, Goswami M, Maduike R, Guerrero JA, Zhang Q, Cavazos A, Ma H, Bivins C, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, Konopleva MY, DiNardo CD
Despite these challenges, the potential benefits are substantial: increased precision, faster optimization of interventions, improved participant safety, and more nuanced insights into the biological variability of neurodegenerative conditions
